Results 41 to 50 of about 167,277 (295)

Strengthening Vaccine Safety Systems, Research, and Regional Collaboration in Africa: A Call to Action

Vaccines
The 8th meeting of the African Advisory Committee on Vaccine Safety (AACVS), constituted in 2021, convened by the Vaccine Research and Innovation Unit within the Vaccine Preventable Diseases Program, WHO Regional Office for Africa, was held virtually ...
Beckie N. Tagbo, Chioma S. Ejekam, Winfred Oppong-Amoako, Tene Marceline Yameogo, Afework Mitiku, Dorothy O. Esangbedo, Nelisiwe Khuzwayo, Gugu Mahlangu, Samia M. Badar, Edinam A. Agbenu, Rhanda M. Adechina, Kwasi A. Nyarko   +11 more
doaj   +1 more source

Analyzing Subnational Immunization Coverage to Catch up and Reach the Unreached in Seven High-Priority Countries in the Eastern Mediterranean Region, 2019–2021

Vaccines
Yearly national immunization coverage reporting does not measure performance at the subnational level throughout the year and conceals inequalities within countries.
Kamal Fahmy, Quamrul Hasan, Md Sharifuzzaman, Yvan Hutin   +3 more
doaj   +1 more source

A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade

Viruses, 2020
On average, there are 3–5 million severe cases of influenza virus infections globally each year. Seasonal influenza vaccines provide limited protection against divergent influenza strains.
Brigette N. Corder, Brianna L. Bullard, Gregory A. Poland, Eric A. Weaver   +3 more
doaj   +1 more source

Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. [PDF]

, 2019
Background: The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8+, but not CD4+, T-cell responses that deliver anti-tumor immunity without autoimmunity in mice.
Abraham, Tara S., Baybutt, Trevor R., Flickinger, John C., Hyslop, Terry, Kraft, Walter K., Sato, Takami, Snook, Adam E., Waldman, Scott A., Xiang, Bo, Zhan, Tingting   +9 more
core   +3 more sources

Heterosubtypic Protection Induced by a Live Attenuated Influenza Virus Vaccine Expressing Galactose-α-1,3-Galactose Epitopes in Infected Cells

mBio, 2020
Anti-galactose-α-1,3-galactose (anti-α-Gal) antibody is naturally expressed at a high level in humans. It constitutes about 1% of immunoglobulins found in human blood.
Li-Meng Yan, Sylvia P. N. Lau, Chek Meng Poh, Vera S. F. Chan, Michael C. W. Chan, Malik Peiris, Leo L. M. Poon   +6 more
doaj   +1 more source

Development of a Universal Influenza Vaccine [PDF]

The Journal of Immunology, 2019
Abstract The severity of the 2017–18 influenza season, combined with the low efficacy for some vaccine components, highlights the need to improve our current seasonal influenza vaccine. Thus, the National Institute of Allergy and Infectious Diseases recently announced a strategic plan to improve current influenza vaccines and eventually ...
Leonardo D Estrada, Stacey Schultz-Cherry   +1 more
openaire   +2 more sources

Protective efficacy of a universal influenza mRNA vaccine against the challenge of H1 and H5 influenza A viruses in mice

mLife, 2023
Current influenza vaccines need to be updated annually owing to constant antigenic drift in the globular head of the viral surface hemagglutinin (HA) glycoprotein. The immunogenic subdominant stem domain of HA is highly conserved and can be recognized by
Yulei Li, Xi Wang, Xi Zeng, Wenbo Ren, Pu Liao, Baoli Zhu   +5 more
doaj   +1 more source

An isolated epizootic of hemorrhagic-like fever in cats caused by a novel and highly virulent strain of feline calicivirus. [PDF]

, 2000
An isolated epizootic of a highly fatal feline calicivirus (FCV) infection, manifested in its severest form by a systemic hemorrhagic-like fever, occurred over a 1-month period among six cats owned by two different employees and a client of a private ...
Elliott, JB, Glasgow, A, Keel, K, Pedersen, NC, Poland, A   +4 more
core   +1 more source

New Technologies for Influenza Vaccines

Microorganisms, 2020
Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to ...
Steven Rockman, Karen L. Laurie, Simone Parkes, Adam Wheatley, Ian G. Barr   +4 more
doaj   +1 more source

Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. [PDF]

, 2016
BACKGROUND: People affected with sickle cell disease are at high risk of infection from Haemophilus influenzae type b. Before the implementation of Haemophilus influenzae type b conjugate vaccination in high-income countries, this was responsible for a ...
Allali, Slimane, Ballas, Samir K., Chalumeau, Martin, de Montalembert, Mariane, Launay, Odile   +4 more
core   +2 more sources